With high-sensitivity and strong negative predictive value, this artificial intelligence (AI)-powered tool enhances early colorectal cancer (CRC) detection and risk stratification in primary care.

Lunit’s SCOPE HER2 AI model demonstrated an 86.7% accuracy compared to pathologist assessments for HER2 immunohistochemistry (IHC).

Doctors and patient advocates supporting pretreatment testing at times challenged FDA and other experts who aren't swayed by available evidence.

A study published in the international journal Antioxidants suggests that l uteolin, an antioxidant found in broccoli and ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") , a biotechnology company focused on the treatment and prevention of cancer, today provided the following letter to shareholders from the Company's, ...

Health Canada has granted market authorisation to Takeda Canada for FRUZAQLA capsules to treat adults with mCRC.

Peering into the body to find and diagnose cancer is all about spotting patterns. Radiologists use x-rays and magnetic ...

Colorectal cancer remains the third most common malignancy worldwide, with advanced stages presenting significant challenges for treatment. A recently published study highlights the potential of ...

Man’s best friend has taken on a remarkable new role in the fight against cancer. Thanks to a groundbreaking collaboration ...

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced ...

The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important ...

The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...